Beam Therapeutics Stock Pattern Recognition Advance Block

BEAM Stock  USD 24.90  -1.18  -4.52%   
The pattern recognition module provides an execution environment for Advance Block recognition and related indicators on Beam Therapeutics. It emphasizes pattern recognition signals tied to momentum and continuation while keeping volatility, risk, and performance context in view.

Recognition
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Advance Block describes upcoming bearish signal for Beam Therapeutics.

Beam Therapeutics Technical Analysis Modules

Most technical analysis of Beam Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Beam from various momentum indicators to cycle indicators. When you analyze Beam charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people. The stock overview for Beam Therapeutics summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/E of 37.48, P/B of 2.15, profit margin of -57.24%. Beam Therapeutics has a market cap of 2.66 B, P/E of 37.48, ROE of -8.11%.

Methodology

Unless otherwise specified, financial data for Beam Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Beam (USA Stocks:BEAM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Beam Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Beam Therapeutics is covered by 17 analysts. 8 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, Jefferies, Goldman Sachs, Evercore ISI, among others. Updates may occur throughout the day.


Learn to be your own money manager

Tracking Beam Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.

Did you try this?

Run Crypto Correlations Now

   

Crypto Correlations

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
All  Next Launch Module

Beam Therapeutics pair trading

Pair trading with Beam Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.

Beam Therapeutics Pair Trading

Beam Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Beam Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Beam Therapeutics when you sell it.
The correlation of Beam Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1.
Correlation analysis and pair trading evaluation for Beam Therapeutics can be used to frame hedging context. The approach can be applied within sectors or across broader universes.
Pair CorrelationCorrelation Matching

More Resources for Beam Stock Analysis

A structured review of Beam Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Beam Therapeutics Stock. Outlined below are key reports that provide context for Beam Therapeutics Stock:
Beam Therapeutics has a market cap of 2.66 B, operating margin of -15.29%, ROE of -8.11%. Use Trending Equities to explore allocation context. This includes a position in Beam Therapeutics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Beam Stock refer to our How to Trade Beam Stock guide.
Analysis related to Beam Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Holdings module to check your current holdings and cash position to determine if your portfolio needs rebalancing.
 Earnings Share
-0.81
 Revenue Per Share
1.413
 Quarterly Revenue Growth
2.795
 Return On Assets
-0.19
 Return On Equity
-0.08
The market value of Beam Therapeutics is measured differently than book value, which reflects Beam accounting equity. Beam Therapeutics' market capitalization is 2.66 B. A P/B ratio of 2.15 indicates the market values Beam Therapeutics above its accounting book value. Enterprise value stands at 1.57 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Beam Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Beam Therapeutics, key inputs include a P/E ratio of 37.48, a P/B ratio of 2.15, a profit margin of -57.24%, and ROE of -8.11%. By contrast, market price reflects the level where buyers and sellers transact.